The present invention generally relates to a system and method for tracking and optimizing health indices. More specifically, in some embodiments the present invention relates to a system and method for tracking and optimizing health indices of one or more individuals having a particular genetic profile and adaptively managing external factors the individual experiences so as to optimize a change in one or more health indices based on the individual's genetic profile.
The cells, organs, systems, and bodies of living organism change over time, growing, improving, or degrading throughout the organism's existence, from birth to death or expiration. The progression of these changes describes a traceable change pattern across time for various aspects of the organism's health and wellbeing.
Scientific advancements have made the ability to determine an individual organism's genetic code a reality, and such information is increasingly utilized. Individuals and their health providers are becoming increasingly aware of the potential impact external factors such as nutrition, lifestyle and medicines have on their health. More recently, scientists are starting to consider wherein individuals with similar genetic codes, experiencing similar external factors, will be predisposed to experience similar health outcomes.
While there has recently been greater attention by consumer organizations, health organizations and the public to the nutritional value of nutritional substances, and the efficacy value of consumables and cosmetic substances, and the impact on health, the industries that provide such products have been slow in responding to this attention. Further, the concept of one's genetic profile playing a role in the real benefit received to an individual from such products, is extremely new, and information available to inform an individual is nearly nonexistent.
An information system allowing an individual organism of a particular genetic profile to adaptively manage major external factors that it may experience, particularly its consumption of nutritional substances and consumables and cosmetic substances, so as to optimize its ΔHs over time, would offer great benefit.
It is an object of the present invention to track and monitor the various aspects associated with the organism's health and wellbeing which can be qualitatively or quantitatively described by various health indices, wherein values associated with the state of each corresponding health index can be assigned. Such health index values can be tracked over time. Changes in these health index values are individually and collectively referred to herein as ΔH.
Is it another object of the present invention to track and monitor individuals with a particular genetic code, and individuals with similar genetic codes, experiencing similar external factors, will be predisposed to experience similar ΔHs. As referred to herein, individuals with genetic traits that predispose them to experience similar ΔHs to other individuals experiencing similar external factors are said to share a similar genetic profile.
In an object of the present invention, an information system is provided with a genetic profile database containing ΔH data for various genetic profiles, wherein each genetic profile includes ΔH data for organisms with genetic traits that predispose them to experience similar ΔHs when experiencing similar external factors.
In a further object of the present invention, an information system is provided with a genetic profile database containing ΔH data for various genetic profiles, wherein each genetic profile includes ΔH data for organisms with genetic traits that predispose them to experience similar ΔHs when consuming similar nutritional substances and consumables and cosmetic substances.
In an object of the present invention, an information system and database are provided to track and store health index values and changes in the health index values (ΔH).
In an object of the present invention, an information system is provided to adaptively manage major external factors that an individual organism having a particular genetic profile may experience, so as to optimize various ΔHs of the individual organism over time.
In a further object of the present invention, an information system is provided to adaptively manage consumption of nutritional substances and consumables and cosmetic substances an individual organism having a particular genetic profile may consume or use, so as to optimize various ΔHs of the individual organism over time.
Embodiments of the present invention relate generally to a system and method for tracking and optimizing health indices.
In some embodiments a system for tracking and/or optimizing one or more health indices associated with an individual is provided comprising: a genetic profile database that collects genetic code data for individuals and identifies corresponding genetic profiles based on the genetic code data; a ΔH database that contains ΔH data associated with each of the genetic profiles, the ΔH data comprising changes in one or more health indices associated with an individuals' health; wherein an individual may track or adaptively manage external factors the individual experiences so as to optimize ΔH based on the individual's particular genetic profile.
The one or more health indices may be comprised of quantitative or qualitative values or scores associated with quality of life, disease state, disease resistance, vital signs, blood chemistry, strength, endurance, metal elasticity, or other factors associated with an individuals' health or wellbeing.
In some embodiments the ΔH database further contains information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, and such information is correlated to one or more of the health indices for a given genetic profile. Optionally, the ΔH database further contains at least one ΔN value, wherein ΔN is the actual residual nutritional value of the nutritional substance an individual plans to prepare or consume, or a change in the nutritional value of the nutritional substance over time. According to embodiments of the present invention, ΔN is a change in a nutritional, organoleptic, or aesthetic value of the nutritional substance and said change comprises any of a maintenance, improvement, or degradation.
In another embodiment, the ΔH database further contains at least one ΔE value, wherein ΔE is the actual residual efficacy value of the consumables or cosmetics substances an individual plans to consume or use, or a change in the efficacy value of the consumables or cosmetics substances over time.
In a further aspect, embodiments of the present invention provide a system for tracking and optimizing health indices of one or more individuals, characterized in that: an individual having a particular genetic profile adaptively manages external factors the individual experiences so as to optimize a change in one or more health indices based on the individual's genetic profile.
The accompanying drawing, which is incorporated in and constitute a part of this specification, exemplify the embodiments of the present invention and, together with the description, serve to explain and illustrate principles of the invention. The drawing is intended to illustrate major features of the exemplary embodiments in a diagrammatic manner. The drawing is not intended to depict every feature of actual embodiments nor relative dimensions of the depicted elements, and is not drawn to scale.
Embodiments of the present invention broadly provide a system and method for tracking and optimizing health indices. In some embodiments a system for tracking and/or optimizing one or more health indices associated with an individual is provided comprising: a genetic profile database that collects genetic code data for individuals and identifies corresponding genetic profiles based on the genetic code data; a ΔH database that contains ΔH data associated with each of the genetic profiles, the ΔH data comprising changes in one or more health indices associated with an individuals' health; wherein an individual may track or adaptively manage external factors the individual experiences so as to optimize ΔH based on the individual's particular genetic profile.
As described herein, various aspects associated with organism's or individual's health and wellbeing which can be qualitatively or quantitatively described by various health indices, is characterized as a health index, and wherein values associated with the state of each corresponding health index can be assigned. Such health index values can be tracked over time. Changes in these health index values are individually and collectively referred to herein as ΔH.
Moreover, individuals with a particular genetic code, and individuals with similar genetic codes, experiencing similar external factors, will be predisposed to experience similar ΔHs. As referred to herein, individuals with genetic traits that predispose them to experience similar ΔHs to other individuals experiencing similar external factors are said to share a similar genetic profile.
Changes in conditions individuals may experience, or to which individuals may be exposed include, but are not limited to, changes in elapsed time, diet, medication, exercise, surgery, and any other change in condition which an individual may experience. Such changes in conditions may concurrently include any combination of changes in conditions to which the individuals may be exposed. For example, in one embodiment, changes in conditions concurrently include elapsed time and diet. In another embodiment, changes in conditions concurrently include elapsed time and medication. In a further embodiment, changes in conditions concurrently include elapsed time, diet, and medication. In a preferred embodiment, changes in conditions concurrently include elapsed time, residual nutritional values of nutritional substances consumed (referred to herein as ΔN information) and residual efficacy values of consumables and cosmetic substances used, including medications (referred to herein as ΔE information).
In
Individual A1 has an initial particular health index value of H2 at T0, for example at birth. Individual A1, which includes those caring for him, has knowledge of his genetic code, “a1”, which may be determined in any fashion known to those skilled in the art, and can be stored in any format known to those skilled in the art. Individual A1 has access to a database corresponding to individuals with various genetic profiles. He may determine and access the genetic profile corresponding to his genetic code a1 by transmitting his genetic code a1 to the database, wherein the database identifies the corresponding genetic profile A1. Each genetic profile contained within the database is referenced to information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, required to optimize various corresponding health indices for individuals with that genetic profile. Such a database is also referred to herein as an ΔH database. Individual A1 additionally has access to information systems with databases containing information regarding the actual residual nutritional value of nutritional substances he plans to prepare or consume, also referred to herein as ΔN information, and the actual residual efficacy value of consumables and cosmetic substances he plans to consume or use, also referred to herein as AE information. Information systems and databases containing such AN and AE information are further described in detail in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851, the teaching and descriptions of all of which are incorporated herein by reference in their entirety.
ΔN refers to the measurement, estimation, and tracking of changes to the nutritional content of a nutritional substance from creation to consumption. This ΔN information could be used, not only by the consumer in selecting nutritional substances to consume but could be used by the other food and beverage industry silos, including creation, preservation, transformation, and conditioning, to make decisions on how to create, handle and process nutritional substances. Additionally, those who sell nutritional substances to consumers, such as restaurants and grocery stores, could communicate perceived qualitative values of the nutritional substance in their efforts to market and position their nutritional substance products. Further, a determinant of price of the nutritional substance could be nutritional, organoleptic, or aesthetic values, and if changes to those values, also referred to herein as ΔN, are perceived as desirable. For example, if a desirable value has been maintained, improved, or minimally degraded, it could be marketed as a premium product. ΔE refers to the change in efficacy values of consumables and cosmetic substances. While the consumables and cosmetic substance industry can be composed of many companies or businesses, it can also be integrated into combinations of business serving many roles or can be one business or even individual. Since ΔE is a measure of the change in an efficacy value of a corresponding consumables and cosmetic substance, knowledge of a prior efficacy value (also referred to as prior efficacy state) of a consumables and cosmetic substance and the ΔE value will provide knowledge of the residual efficacy value (also referred to as current efficacy value or current efficacy state).
ΔE information for the consumables and cosmetic substance may be stored in a dynamic efficacy value database. The database may also contain sensed physical attribute values for known consumables and cosmetic substances at known efficacy states, also referred to herein as a consumables and cosmetic substance attribute library. The consumables and cosmetic substance attribute library can be utilized for determining the identity and current efficacy state of a consumables and cosmetic substance. The database can be connected to the other modules by a variety of communication systems, such as paper, computer networks, the internet and telecommunication systems, such as wireless telecommunication systems. In a system capable of receiving and processing real time consumer feedback and updates regarding changes in an efficacy value of a corresponding consumables and cosmetic substance, or ΔE, consumers can even play a role in updating the dynamic efficacy value database with observed or measured information about the consumables and cosmetic substances they have purchased and/or dispensed for consumption and/or consumed, so that the information is available and useful to determine a corresponding ΔE, and may further be available to others in the consumables and cosmetic substance supply system.
The ΔH database containing information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, required to optimize a particular health index for individuals with known genetic profiles, can be utilized to adaptively recommend the consumption or use of particular nutritional substances and consumables and cosmetic substances responsive to: an individual's genetic code; tracked information regarding actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used by an individual; and ΔN and ΔE information for nutritional substances and consumables and cosmetic substances currently being considered by the individual.
In an example, individual A1 utilizes information regarding his genetic code “a1” to identify a corresponding genetic profile in the AH database, wherein the corresponding genetic profile “A” is referenced to information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, required to optimize particular health indices for individuals with genetic profile “A”. Input from individual A1 may also include one or more particular health indices of interest, and may further include information regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used individual A1, wherein such information may have been acquired through his use of the information systems such as described in detail in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851, the teaching and descriptions of all of which are incorporated herein by reference in their entirety. For example, a consumer interface provided with, or communicating with, a local storage container may enable the local storage container to communicate to the consumer that it contains consumables and cosmetic substance, information related to its ΔE, including current residual efficacy values. Information regarding the dynamically-labeled nutritional substances from each stage of the production of the nutritional substances from creation to consumption may be collected, tracked, and organized. The information regarding the dynamically-labeled nutritional substances may be openly available and openly integrated at any point in time. The integration and availability of the information may be enabled by dynamic labeling provided with the nutritional substances, which includes a unique nutritional substance identifier.
Responsive to the input from individual A1, the AH database adaptively determines and provide recommendations regarding current needs for consumption or use of nutritional substances and consumables and cosmetic substances so as to optimize corresponding health indices. The adaptive nature of such recommendations takes into account deficient, proper, or excesses levels of particular nutritional values and efficacy values. For example, the input regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used by individual A1 may compared to, or otherwise evaluated against, the AH database for genetic profile “A”, in order to determine currently needed levels of corresponding nutritional and efficacy values. Using the adaptively determined recommendations from the AH database regarding needed nutritional and efficacy values, individual A1 can further utilize the information systems described fully and in detail in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851 to accomplish conditioning, dispensing, consumption, and use of nutritional substances and consumables and cosmetic substances to assure the consumption and use of required residual nutritional and efficacy values. For example, a dispensing module may be used to dispense consumables and cosmetic substances immediately before consumption. The dispensing module may include, but is not limited to, a volumetric-based dispensing system, a weight-based dispensing machine, a counting device, a controlled storage environment, a storage container tracking storage conditions such as temperature, an individual such as a doctor, pharmacist, nurse, patient, etc. It may also be systems used by commercial establishments to prepare consumables and cosmetic substance for consumers, such as equipment used by a hospital or a compounding pharmacy, or other devices located at businesses which provide consumables and cosmetic substances to consumers. Such consumables and cosmetic substances could be for consumption at the business or for the consumer to take out from the business. The dispensing module can also be any combination of these systems, machines, devices, equipment, or individuals used to dispense consumables and cosmetic substances for consumption by consumers. A consumption module may be implemented to select consumables and cosmetic substances according to ΔE information and residual efficacy values. This will further allow consumers to make informed decisions regarding consumables and cosmetic substance additives, preservatives, origins, traceability, and other consumables and cosmetic substance attributes that may also be tracked through an information module. Furthermore, the consumption module may provide information for the consumer to operate the dispensing module with adaptive dispensing parameters, wherein the adaptive dispensing parameters are responsive to a ΔE or corresponding residual efficacy value of the consumables and cosmetic substance being dispensed and may further be responsive to the consumer's input related to the ΔE, the corresponding efficacy value, or the corresponding amount of efficacy content to be dispensed. In this way, the amount of efficacy content in the dispensed consumables and cosmetic substance can be optimized or maintained, according to, but not limited to: a target amount based on the consumer's input regarding his needs or preference; a target amount established by the provider of the consumables and cosmetic substance, such as the transformer; a target amount established by a dispenser of the consumables and cosmetic substance, such as a service provider; or a target amount equal to a predetermined amount of efficacy content recommended by the labeling or product information provided with the consumables and cosmetic substance. In this way, individual A1 is able to achieve the highest corresponding health index at any given time from To, for example his birth, to time T5, for example his expiration or death.
As demonstrated by this example, individual A1's ultimate consumption and use of nutritional substances and consumables and cosmetic substances has benefited from adaptively determined recommendations responsive to: input from individual A1 regarding his genetic code “a1”; input from individual A1 regarding particular health indices of interest; input regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances individual A1 has already consumed or used; and ΔN and ΔE information for nutritional substances and consumables and cosmetic substances currently being considered for conditioning, consumption, dispensing, or use by individual A1. In this way, individual A1 has optimized the particular health indices and achieved the highest corresponding health index at any given time from T0, for example his birth, to time T5, for example his expiration.
In a further example, individual A2 has a unique genetic code “a2”, but has the same genetic profile “A” as individual A1, and accordingly has an initial particular health index value of H2 corresponding to the particular health index value at T0. However, individual A2 does not utilize the ΔH database. Accordingly, individual A2 is unable to obtain adaptively determined recommendations regarding nutritional and efficacy values needed to optimize the particular health index for individuals with his genetic profile “A”. Therefore, he is not able to achieve the highest corresponding health index at any given time from T0, for example his birth, to time T2, for example his expiration.
It is clear from
In an example, individual B1 utilizes information regarding his genetic code “b1” to identify a corresponding genetic profile in the ΔH database, wherein the corresponding genetic profile “B” is referenced to information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, required to optimize particular health indices for individuals with genetic profile “B”. Input from individual B1 may also include one or more particular health indices of interest, and may further include information regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used individual B1, wherein such information may have been acquired through his use of the information systems described in detail in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851, the teaching and descriptions of all of which are incorpated herein by reference in their entirety. Responsive to the input from individual B1, the ΔH database adaptively determines and provide recommendations regarding current needs for consumption or use of nutritional substances and consumables and cosmetic substances so as to optimize corresponding health indices. The adaptive nature of such recommendations takes into account deficient, proper, or excesses levels of particular nutritional values and efficacy values. For example, the input regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used by individual B1 may compared to, or otherwise evaluated against, the ΔH database for genetic profile “B”, in order to determine currently needed levels of corresponding nutritional and efficacy values. Using the adaptively determined recommendations from the ΔH database regarding needed nutritional and efficacy values, individual B1 can further utilize the information systems described fully and in detail in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851 to accomplish conditioning, dispensing, consumption, and use of nutritional substances and consumables and cosmetic substances to assure the consumption and use of required residual nutritional and efficacy values. In this way, individual B1 is able to achieve the highest corresponding health index at any given time from T0, for example his birth, to time T4, for example his expiration.
As demonstrated by this example, individual B1's ultimate consumption and use of nutritional substances and consumables and cosmetic substances has benefited from adaptively determined recommendations responsive to: input from individual B1 regarding his genetic code “b1”; input from individual B1 regarding particular health indices of interest; input regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances individual B1 has already consumed or used; and ΔN and ΔE information for nutritional substances and consumables and cosmetic substances currently being considered for conditioning, consumption, dispensing, or use by individual B1. In this way, individual B1 has optimized the particular health indices and achieved the highest corresponding health index at any given time from T0, for example his birth, to time T4, for example his expiration.
In a further example, individual B2 has a unique genetic code “b2”, but has the same genetic profile “B” as individual B1, and accordingly has an initial particular health index value of H1 corresponding to the particular health index value at T0. However, individual B2 does not begin to utilize the ΔH database until T1. Accordingly, individual B2 is unable to obtain adaptively determined recommendations regarding nutritional and efficacy values needed to optimize the particular health index for individuals with his genetic profile “B”. Therefore, he is not able to achieve the highest corresponding health index at any given time from T0, for example his birth, to time T1 when he begins to utilize the ΔH database.
At time T1 individual B2 begins to utilize the information regarding his genetic code “b2” to identify a corresponding genetic profile in the ΔH database, wherein the corresponding genetic profile “B” is referenced to information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, required to optimize particular health indices for individuals with genetic profile “B”. Input from individual B2 may also include one or more particular health indices of interest, and may further include information regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used individual B2, wherein such information may have been acquired through his use of the information systems described in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851, the teaching and descriptions of all of which are incorpated herein by reference in their entirety. Responsive to the input from individual B2, the ΔH database adaptively determines and provide recommendations regarding current needs for consumption or use of nutritional substances and consumables and cosmetic substances so as to optimize corresponding health indices. The adaptive nature of such recommendations takes into account deficient, proper, or excesses levels of particular nutritional values and efficacy values. For example, the input regarding the actual residual nutritional and efficacy values of nutritional substances and consumables and cosmetic substances already consumed or used by individual B2 may compared to, or otherwise evaluated against, the ΔH database for genetic profile “B”, in order to determine currently needed levels of corresponding nutritional and efficacy values. Using the adaptively determined recommendations from the ΔH database regarding needed nutritional and efficacy values, individual B2 can further utilize the information systems described fully and in detail in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851 to accomplish conditioning, dispensing, consumption, and use of nutritional substances and consumables and cosmetic substances to assure the consumption and use of required residual nutritional and efficacy values. In this way, individual B2 is able to achieve the highest corresponding health index at any given time from T1, when he begins utilizing the adaptively determined recommendations, to time T3, for example his expiration.
It is clear from
The genetic profile database 230 may be created by: determining the genetic code of many individuals, and preferably, all individuals; tracking and storing their various health index values over time (ΔH data 250); referencing the tracked and stored data to its corresponding genetic code; and analyzing the data to identify distinct genetic profiles, wherein each genetic profile includes ΔH data for individuals with genetic traits that predispose them to experience similar ΔHs when consuming similar nutritional substances and consumables and cosmetic substances.
The data for each genetic profile may be further analyzed to identify information regarding nutritional values of nutritional substances and efficacy values of consumables and cosmetic substances, and combinations thereof, required to optimize various corresponding health indices for individuals with that genetic profile. Such information may comprise the ΔH database 220.
By determining an individual's genetic code, the ΔH database 220 could be used in many ways to improve the health, wellbeing, and/or longevity of the individual. For example, if someone has a large tumor then his doctor can access the ΔH database 220 and determine the best course of action for individuals with the same genetic profile from the generic profile database 230. In this case the ΔH database 220 and genetic profile database 230 may show that individuals sharing this genetic profile lived a long time without the need for the tumor to be removed simply by taking care to not consume particular nutritional values found in specific nutritional substances, for example, specific nutritional values found in milk that accelerate tumors in men but not in women. In contrast a doctor might identify another very small tumor that given the individuals genetic profile, had to be extracted with urgency as regardless of nutritional substance and consumables and cosmetic substances consumed or used, it has a devastating effect if it remained in his body.
Of particular advantage, controller 240 is configured or adapted to process and correlate the genetic profile data and ΔH data. Such processing and correlation may produce an output that is used to determine desired treatment to improve the health, wellbeing, and/or longevity of the individual. Optionally, nutritional substance information and/or consumable and cosmetics data 270 may also be correlated or processed by controller 240 to provide further output that is used to determine desired treatment to improve the health, wellbeing, and/or longevity.
In an alternate embodiment, controller 230 references nutritional substance information and/or consumables and cosmetics information from database 270 to genetic profile database 230 to inform the consumer 260 via consumer interface 280 what impact a particular nutritional substance and/or consumable or cosmetic may have on the consumer given a particular genetic profile.
The health index system 200 can be implemented with discreet devices. Data may be provided in a number of ways, such as by optical reader such as a barcode scanner or camera capable of discerning reference information, by reader such wireless signal reader, reading RFID labels, or near field IDs, by manual input via a keyboard or touch screen, and the like. Controller 240 can be a computer, microcontroller, personal computer, laptop computer, tablet computer, or smartphone. Consumer interface 280 can be a standalone touchpad display panel which allows interaction with the consumer, but is preferably integrated into controller 240.
The utilization of the information systems comprising a AH database, in conjunction with the nutritional substance and consumables and cosmetic substance information systems described in copending U.S. patent application Ser. Nos. 13/771,004, 13/888,353, 13/948,004, 13/948,078, 13/948,083, and 14/044,851, dynamically connects participants and stake holders across the nutritional substance/consumables and cosmetic substance ecosystem in order to improve individuals health, wellbeing, and quality of life. For example, the information module may be implemented as a massive, multidimensional database operated on multiple computing devices across an interconnecting network. Such a database could be hosted by a plurality of nutritional substance creators, preservers, transformers, conditioners, or consumers. In some embodiments, the information module may be maintained and operated by a global entity which operates the system for the benefit of all participants in a nutritional substance supply system. In such an information module, the global entity could be remunerated on a per-transaction basis for receiving nutritional substance information or providing nutritional substance information.
Access to the information module by participants in the supply chain could be at no charge. However, the global entity could receive remuneration for access by non-participants such as research and marketing organizations. Alternatively, participants in the supply chain could pay to advertise to other participants in the supply chain as part of their access to the information in information module.
Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense (i.e., to say, in the sense of “including, but not limited to”), as opposed to an exclusive or exhaustive sense. As used herein, the terms “connected,” “coupled,” or any variant thereof means any connection or coupling, either direct or indirect, between two or more elements. Such a coupling or connection between the elements can be physical, logical, or a combination thereof. Additionally, the words “herein,” “above,” “below,” and words of similar import, when used in this application, refer to this application as a whole and not to any particular portions of this application. Where the context permits, words in the above Detailed Description using the singular or plural number may also include the plural or singular number respectively. The word “or,” in reference to a list of two or more items, covers all of the following interpretations of the word: any of the items in the list, all of the items in the list, and any combination of the items in the list.
The above Detailed Description of examples of the invention is not intended to be exhaustive or to limit the invention to the precise form disclosed above. While specific examples for the invention are described above for illustrative purposes, various equivalent modifications are possible within the scope of the invention, as those skilled in the relevant art will recognize While processes or blocks are presented in a given order in this application, alternative implementations may perform routines having steps performed in a different order, or employ systems having blocks in a different order. Some processes or blocks may be deleted, moved, added, subdivided, combined, and/or modified to provide alternative or sub-combinations. Also, while processes or blocks are at times shown as being performed in series, these processes or blocks may instead be performed or implemented in parallel, or may be performed at different times. Further any specific numbers noted herein are only examples. It is understood that alternative implementations may employ differing values or ranges.
The various illustrations and teachings provided herein can also be applied to systems other than the system described above. The elements and acts of the various examples described above can be combined to provide further implementations of the invention.
Any patents and applications and other references noted above, including any that may be listed in accompanying filing papers, are incorporated herein by reference. Aspects of the invention can be modified, if necessary, to employ the systems, functions, and concepts included in such references to provide further implementations of the invention.
These and other changes can be made to the invention in light of the above Detailed Description. While the above description describes certain examples of the invention, and describes the best mode contemplated, no matter how detailed the above appears in text, the invention can be practiced in many ways. Details of the system may vary considerably in its specific implementation, while still being encompassed by the invention disclosed herein. As noted above, particular terminology used when describing certain features or aspects of the invention should not be taken to imply that the terminology is being redefined herein to be restricted to any specific characteristics, features, or aspects of the invention with which that terminology is associated. In general, the terms used in the following claims should not be construed to limit the invention to the specific examples disclosed in the specification, unless the above Detailed Description section explicitly defines such terms. Accordingly, the actual scope of the invention encompasses not only the disclosed examples, but also all equivalent ways of practicing or implementing the invention under the claims.
While certain aspects of the invention are presented below in certain claim forms, the applicant contemplates the various aspects of the invention in any number of claim forms. For example, while only one aspect of the invention is recited as a means-plus-function claim under 35 U.S.C. § 112, sixth paragraph, other aspects may likewise be embodied as a means-plus-function claim, or in other forms, such as being embodied in a computer-readable medium. Any claims intended to be treated under 35 U.S.C. § 112, ¶6 will begin with the words “means for.” Accordingly, the applicant reserves the right to add additional claims after filing the application to pursue such additional claim forms for other aspects of the invention.
This application claims the benefit of, and priority to, U.S. Provisional Patent Application Ser. No. 61/888,451 filed Oct. 8, 2013, titled “SYSTEM FOR TRACKING AND OPTIMIZING HEALTH INDICES,” the entire disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4225410 | Pace | Sep 1980 | A |
4555930 | Leach et al. | Dec 1985 | A |
4644154 | Brogardh et al. | Feb 1987 | A |
4650766 | Harm et al. | Mar 1987 | A |
4674320 | Hirschfeld | Jun 1987 | A |
D333782 | van Berlo | Mar 1993 | S |
5250789 | Johnsen | Oct 1993 | A |
5412560 | Dennision | May 1995 | A |
5442669 | Medin | Aug 1995 | A |
5478900 | Amano et al. | Dec 1995 | A |
5478989 | Shepley | Dec 1995 | A |
5478990 | Montanari et al. | Dec 1995 | A |
5673691 | Abrams et al. | Oct 1997 | A |
5697177 | Ludlow et al. | Dec 1997 | A |
5804803 | Cragun et al. | Sep 1998 | A |
5853790 | Glancy | Dec 1998 | A |
5872721 | Huston et al. | Feb 1999 | A |
5937387 | Summerell | Aug 1999 | A |
5954640 | Szabo | Sep 1999 | A |
6012415 | Linseth | Jan 2000 | A |
6119531 | Wendte et al. | Sep 2000 | A |
6182725 | Sorvik | Feb 2001 | B1 |
6211789 | Oldham et al. | Apr 2001 | B1 |
6270724 | Woodaman | Aug 2001 | B1 |
6276264 | Dumm | Aug 2001 | B1 |
6310964 | Mohan et al. | Oct 2001 | B1 |
6325878 | Borgstrom | Dec 2001 | B1 |
6356940 | Short | Mar 2002 | B1 |
6387049 | Moore | May 2002 | B1 |
6444233 | Arntzen et al. | Sep 2002 | B1 |
6483434 | Umiker | Nov 2002 | B1 |
6491217 | Catan | Dec 2002 | B2 |
6502411 | Okamoto | Jan 2003 | B2 |
6512919 | Ogasawara | Jan 2003 | B2 |
6513532 | Mault et al. | Feb 2003 | B2 |
6538215 | Montagnino et al. | Mar 2003 | B2 |
6549818 | Ali | Apr 2003 | B1 |
6553386 | Alabaster | Apr 2003 | B1 |
6554182 | Magnusson et al. | Apr 2003 | B1 |
6556963 | Tetzlaff | Apr 2003 | B1 |
6571603 | Doleman et al. | Jun 2003 | B1 |
D478773 | Palen | Aug 2003 | S |
6616047 | Catan | Sep 2003 | B2 |
6631333 | Lewis et al. | Oct 2003 | B1 |
6671698 | Pickett et al. | Dec 2003 | B2 |
6676014 | Catan | Jan 2004 | B2 |
6689398 | Haridas et al. | Feb 2004 | B2 |
6691135 | Pickett et al. | Feb 2004 | B2 |
6716462 | Prosise et al. | Apr 2004 | B2 |
6773926 | Freund et al. | Aug 2004 | B1 |
6789021 | Rendahl et al. | Sep 2004 | B2 |
6844197 | Doleman et al. | Jan 2005 | B1 |
6874000 | Sholl et al. | Mar 2005 | B2 |
6888458 | Carlson | May 2005 | B2 |
6953342 | Bisogno | Oct 2005 | B2 |
6975910 | Brown et al. | Dec 2005 | B1 |
6982640 | Lindsay et al. | Jan 2006 | B2 |
7024369 | Brown et al. | Apr 2006 | B1 |
7076438 | Tobelmann et al. | Jul 2006 | B1 |
7085777 | Beck et al. | Aug 2006 | B2 |
7090638 | Vidgen | Aug 2006 | B2 |
7103481 | Negri | Sep 2006 | B2 |
7151447 | Willms et al. | Dec 2006 | B1 |
7152040 | Hawthorne et al. | Dec 2006 | B1 |
D534758 | Lee et al. | Jan 2007 | S |
D539072 | Kawata et al. | Mar 2007 | S |
D539595 | Okuda et al. | Apr 2007 | S |
D540613 | Jeon | Apr 2007 | S |
D541578 | Jeon | May 2007 | S |
7212955 | Kirshenbau et al. | May 2007 | B2 |
7213743 | Carlson et al. | May 2007 | B2 |
7215420 | Gellerman et al. | May 2007 | B2 |
7237400 | Owada | Jul 2007 | B2 |
7256699 | Tethrake et al. | Aug 2007 | B2 |
7275863 | Akers et al. | Oct 2007 | B1 |
7295889 | Lahteenmaki | Nov 2007 | B2 |
D560960 | Hillmann et al. | Feb 2008 | S |
7357316 | Heckel et al. | Apr 2008 | B2 |
7359802 | Lewis et al. | Apr 2008 | B1 |
7372003 | Kates | May 2008 | B2 |
7396550 | Angel | Jul 2008 | B2 |
7403855 | Fuessley et al. | Jul 2008 | B2 |
7440901 | Dlott et al. | Oct 2008 | B1 |
7474965 | Johnson et al. | Jan 2009 | B2 |
7571676 | Nelson et al. | Aug 2009 | B2 |
7620531 | Johnson | Nov 2009 | B1 |
D607264 | Lee | Jan 2010 | S |
7681383 | Argetsinger et al. | Mar 2010 | B2 |
D618488 | Knochner | Jun 2010 | S |
7743591 | Meier et al. | Jun 2010 | B2 |
7797204 | Balent | Sep 2010 | B2 |
7836876 | Schellenberg | Nov 2010 | B2 |
7840359 | Hsiung et al. | Nov 2010 | B2 |
7854108 | Koselka et al. | Dec 2010 | B2 |
D633326 | Shin et al. | Mar 2011 | S |
7951079 | Moore | May 2011 | B1 |
7957850 | Anderson | Jun 2011 | B2 |
7996134 | Roberts | Aug 2011 | B2 |
8009048 | Hyde et al. | Aug 2011 | B2 |
8033237 | Havens et al. | Oct 2011 | B2 |
8082809 | Luellen et al. | Dec 2011 | B2 |
D654299 | Benold | Feb 2012 | S |
8112303 | Eglen et al. | Feb 2012 | B2 |
D657607 | Ohmae et al. | Apr 2012 | S |
8193474 | Harris | Jun 2012 | B2 |
D665220 | Ohmae et al. | Aug 2012 | S |
8285593 | Bhatt et al. | Oct 2012 | B2 |
8314701 | Grieco et al. | Nov 2012 | B2 |
D673001 | Becze et al. | Dec 2012 | S |
8393137 | Crosby | Mar 2013 | B1 |
8403215 | Aihara et al. | Mar 2013 | B2 |
8490862 | Minvielle | Jul 2013 | B1 |
8626796 | McBride et al. | Jan 2014 | B2 |
8631050 | Gayle | Jan 2014 | B1 |
D702482 | Davis et al. | Apr 2014 | S |
8796510 | Heard et al. | Aug 2014 | B2 |
9016193 | Minvielle | Apr 2015 | B2 |
20020004749 | Froseth et al. | Jan 2002 | A1 |
20020011567 | Ozanich | Jan 2002 | A1 |
20020040564 | Killingbeck et al. | Apr 2002 | A1 |
20020059175 | Nakano | May 2002 | A1 |
20020091593 | Fowler | Jul 2002 | A1 |
20020106432 | Yamagata et al. | Aug 2002 | A1 |
20020125313 | Broff | Sep 2002 | A1 |
20020168456 | Robbins | Nov 2002 | A1 |
20030006281 | Thomas et al. | Jan 2003 | A1 |
20030027161 | Bejanin et al. | Feb 2003 | A1 |
20030099157 | Quine | May 2003 | A1 |
20030136960 | Goodman et al. | Jul 2003 | A1 |
20030163354 | Shamoun | Aug 2003 | A1 |
20030165602 | Garwood | Sep 2003 | A1 |
20030185937 | Garwood | Oct 2003 | A1 |
20030185948 | Garwood | Oct 2003 | A1 |
20030227392 | Ebert et al. | Dec 2003 | A1 |
20040045202 | Arrendale, III et al. | Mar 2004 | A1 |
20040083201 | Sholl et al. | Apr 2004 | A1 |
20040100380 | Lindsay et al. | May 2004 | A1 |
20040130714 | Gellerman et al. | Jul 2004 | A1 |
20040147038 | Lewis et al. | Jul 2004 | A1 |
20040152131 | Hsieh | Aug 2004 | A1 |
20040167724 | Federer et al. | Aug 2004 | A1 |
20040191382 | Cooper et al. | Sep 2004 | A1 |
20040201454 | Waterhouse et al. | Oct 2004 | A1 |
20040215402 | Hsiung et al. | Oct 2004 | A1 |
20040267098 | Moore | Dec 2004 | A1 |
20050001728 | Appelt et al. | Jan 2005 | A1 |
20050027726 | Guivarch et al. | Feb 2005 | A1 |
20050049920 | Day et al. | Mar 2005 | A1 |
20050075900 | Arguimbau, III | Apr 2005 | A1 |
20050079491 | Donne-Gousse et al. | Apr 2005 | A1 |
20050168325 | Lievre et al. | Aug 2005 | A1 |
20050171738 | Kadaba | Aug 2005 | A1 |
20050247213 | Slilaty | Nov 2005 | A1 |
20050248455 | Pope et al. | Nov 2005 | A1 |
20050251449 | Pape et al. | Nov 2005 | A1 |
20060015371 | Knauf et al. | Jan 2006 | A1 |
20060061454 | Debord et al. | Mar 2006 | A1 |
20060062835 | Weil | Mar 2006 | A1 |
20060073483 | White et al. | Apr 2006 | A1 |
20060078658 | Owens et al. | Apr 2006 | A1 |
20060099310 | Koekkoek | May 2006 | A1 |
20060130498 | Joshi et al. | Jun 2006 | A1 |
20060172048 | Etchells et al. | Aug 2006 | A1 |
20060178841 | Fernandez | Aug 2006 | A1 |
20060200480 | Harris et al. | Sep 2006 | A1 |
20060228428 | Kang et al. | Oct 2006 | A1 |
20060240174 | Jung et al. | Oct 2006 | A1 |
20060256132 | Shin et al. | Nov 2006 | A1 |
20060277064 | Cannata | Dec 2006 | A1 |
20060286211 | Lang | Dec 2006 | A1 |
20070016852 | Kim et al. | Jan 2007 | A1 |
20070036840 | Tuduri et al. | Feb 2007 | A1 |
20070055551 | Szabo | Mar 2007 | A1 |
20070055573 | Grell | Mar 2007 | A1 |
20070059402 | Barmore | Mar 2007 | A1 |
20070118394 | Cahoon | May 2007 | A1 |
20070191689 | Elitok | Aug 2007 | A1 |
20070209656 | Lee | Sep 2007 | A1 |
20070258048 | Pitchers | Nov 2007 | A1 |
20070269557 | Culver et al. | Nov 2007 | A1 |
20070294129 | Froseth et al. | Dec 2007 | A1 |
20070298147 | Haus | Dec 2007 | A1 |
20080058783 | Altshuler et al. | Mar 2008 | A1 |
20080059342 | Culver et al. | Mar 2008 | A1 |
20080077455 | Gilboa | Mar 2008 | A1 |
20080083825 | Yang et al. | Apr 2008 | A1 |
20080091705 | McBride et al. | Apr 2008 | A1 |
20080158543 | Puskas et al. | Jul 2008 | A1 |
20080171120 | Willett | Jul 2008 | A1 |
20080183588 | Agrawal et al. | Jul 2008 | A1 |
20080186175 | Stern | Aug 2008 | A1 |
20080195456 | Fitzpatrick et al. | Aug 2008 | A1 |
20080254449 | Plante | Oct 2008 | A1 |
20080275309 | Stivoric et al. | Nov 2008 | A1 |
20090029014 | Walter et al. | Jan 2009 | A1 |
20090065570 | Peters et al. | Mar 2009 | A1 |
20090070040 | Rabinovitch et al. | Mar 2009 | A1 |
20090099873 | Kurple | Apr 2009 | A1 |
20090157460 | Narayanaswamy | Jun 2009 | A1 |
20090177068 | Stivoric et al. | Jul 2009 | A1 |
20090202700 | Bunke et al. | Aug 2009 | A1 |
20090208607 | Bunke et al. | Aug 2009 | A1 |
20090232958 | Samoto et al. | Sep 2009 | A1 |
20090275002 | Hoggle | Nov 2009 | A1 |
20090276912 | Sherman et al. | Nov 2009 | A1 |
20090278685 | Potyrailo et al. | Nov 2009 | A1 |
20090282004 | Williams | Nov 2009 | A1 |
20090283517 | MacKay et al. | Nov 2009 | A1 |
20090286212 | Gordon | Nov 2009 | A1 |
20090288606 | Zimmerman | Nov 2009 | A1 |
20100055653 | Miller-Kovach et al. | Mar 2010 | A1 |
20100076585 | Mayer et al. | Mar 2010 | A1 |
20100097193 | Tang | Apr 2010 | A1 |
20100102959 | Ashrafzadeh et al. | Apr 2010 | A1 |
20100106625 | McCoy | Apr 2010 | A1 |
20100106626 | Ashrafzadeh et al. | Apr 2010 | A1 |
20100117819 | Murray | May 2010 | A1 |
20100119659 | Ovadia et al. | May 2010 | A1 |
20100135211 | Park et al. | Jun 2010 | A1 |
20100152687 | Carlozzi | Jun 2010 | A1 |
20100175886 | Bohacs et al. | Jul 2010 | A1 |
20100198605 | Saulet | Aug 2010 | A1 |
20100216098 | Montgomery | Aug 2010 | A1 |
20100216136 | Man et al. | Aug 2010 | A1 |
20100218044 | Roblett et al. | Aug 2010 | A1 |
20100228160 | Schweizer | Sep 2010 | A1 |
20100268658 | Medo et al. | Oct 2010 | A1 |
20100280895 | Mottola | Nov 2010 | A1 |
20100287101 | Ishikawa et al. | Nov 2010 | A1 |
20110029364 | Roeding et al. | Feb 2011 | A1 |
20110082711 | Poeze et al. | Apr 2011 | A1 |
20110124096 | Philipak et al. | May 2011 | A1 |
20110197827 | Chang | Aug 2011 | A1 |
20110204137 | Scharfenort et al. | Aug 2011 | A1 |
20110217205 | Peeters | Sep 2011 | A1 |
20110236862 | Culver et al. | Sep 2011 | A1 |
20110258130 | Grabiner et al. | Oct 2011 | A1 |
20110259960 | Baarman et al. | Oct 2011 | A1 |
20110301441 | Bandic et al. | Dec 2011 | A1 |
20110302050 | Kildevaeld | Dec 2011 | A1 |
20110318717 | Adamowicz | Dec 2011 | A1 |
20120004935 | Winkler | Jan 2012 | A1 |
20120005105 | Beier et al. | Jan 2012 | A1 |
20120009550 | Gayle | Jan 2012 | A1 |
20120016814 | Evans | Jan 2012 | A1 |
20120027897 | Innocenzi | Feb 2012 | A1 |
20120052162 | Goulart | Mar 2012 | A1 |
20120055718 | Chen | Mar 2012 | A1 |
20120083669 | Abujbara | Apr 2012 | A1 |
20120085828 | Ziegler | Apr 2012 | A1 |
20120085829 | Ziegler | Apr 2012 | A1 |
20120105424 | Lee et al. | May 2012 | A1 |
20120135455 | Nerin De La Puerta et al. | May 2012 | A1 |
20120169469 | Butler et al. | Jul 2012 | A1 |
20120173269 | Omidi | Jul 2012 | A1 |
20120179665 | Baarman et al. | Jul 2012 | A1 |
20120199643 | Minnick et al. | Aug 2012 | A1 |
20120203572 | Christensen | Aug 2012 | A1 |
20120216911 | Bartholomew et al. | Aug 2012 | A1 |
20120251663 | Prins et al. | Oct 2012 | A1 |
20120274470 | Sandvick | Nov 2012 | A1 |
20120290051 | Boyden et al. | Nov 2012 | A1 |
20120315609 | Miller-Kovach et al. | Dec 2012 | A1 |
20120321759 | Marinkovich et al. | Dec 2012 | A1 |
20130033031 | Key | Feb 2013 | A1 |
20130048736 | Wien | Feb 2013 | A1 |
20130048737 | Baym et al. | Feb 2013 | A1 |
20130052616 | Silverstein et al. | Feb 2013 | A1 |
20130080784 | Oertli | Mar 2013 | A1 |
20130105565 | Kamprath | May 2013 | A1 |
20130117310 | Chai et al. | May 2013 | A1 |
20130209615 | Lee et al. | Aug 2013 | A1 |
20130231711 | Kaib | Sep 2013 | A1 |
20130269297 | Minvielle | Oct 2013 | A1 |
20130269454 | Minvielle | Oct 2013 | A1 |
20130269537 | Minvielle | Oct 2013 | A1 |
20130269538 | Minvielle | Oct 2013 | A1 |
20130269542 | Minvielle | Oct 2013 | A1 |
20130269543 | Minvielle | Oct 2013 | A1 |
20130269544 | Minvielle | Oct 2013 | A1 |
20130270337 | Minvielle | Oct 2013 | A1 |
20130273217 | Minvielle | Oct 2013 | A1 |
20130273222 | Minvielle | Oct 2013 | A1 |
20130273507 | Minvielle | Oct 2013 | A1 |
20130273509 | Mutti | Oct 2013 | A1 |
20130275037 | Minvielle | Oct 2013 | A1 |
20130275318 | Minvielle | Oct 2013 | A1 |
20130275342 | Minvielle | Oct 2013 | A1 |
20130275343 | Minvielle | Oct 2013 | A1 |
20130275370 | Minvielle | Oct 2013 | A1 |
20130275426 | Minvielle | Oct 2013 | A1 |
20130275439 | Minvielle | Oct 2013 | A1 |
20130275460 | Minvielle | Oct 2013 | A1 |
20130275477 | Minvielle | Oct 2013 | A1 |
20130276644 | Minvielle | Oct 2013 | A1 |
20130290364 | Minvielle | Oct 2013 | A1 |
20130295532 | Minvielle | Nov 2013 | A1 |
20130297642 | Minvielle | Nov 2013 | A1 |
20130309138 | Minvielle | Nov 2013 | A1 |
20130309636 | Minvielle | Nov 2013 | A1 |
20130309637 | Minvielle | Nov 2013 | A1 |
20130310955 | Minvielle | Nov 2013 | A1 |
20130337516 | Herrema | Dec 2013 | A1 |
20140018636 | Contant et al. | Jan 2014 | A1 |
20140037805 | Minvielle | Feb 2014 | A1 |
20140038140 | Minvielle | Feb 2014 | A1 |
20140041532 | Minvielle | Feb 2014 | A1 |
20140041533 | Minvielle | Feb 2014 | A1 |
20140061296 | Minvielle | Mar 2014 | A1 |
20140069838 | Minvielle | Mar 2014 | A1 |
20140191025 | Minvielle | Jul 2014 | A1 |
20140214714 | Minvielle | Jul 2014 | A1 |
20140236359 | Minvielle | Aug 2014 | A1 |
20140290395 | Minvielle | Oct 2014 | A1 |
20140290396 | Minvielle | Oct 2014 | A1 |
20140364971 | Minvielle | Dec 2014 | A1 |
20140364972 | Minvielle | Dec 2014 | A1 |
20150012122 | Minvielle | Jan 2015 | A1 |
20150017252 | Garland et al. | Jan 2015 | A1 |
20150037764 | Minvielle | Feb 2015 | A1 |
20150051841 | Minvielle | Feb 2015 | A1 |
20150057773 | Minvielle | Feb 2015 | A1 |
20150100462 | Minvielle | Apr 2015 | A1 |
Number | Date | Country |
---|---|---|
10 2005 040206 | Feb 2007 | DE |
1 117 055 | Jul 2001 | EP |
1 253 203 | Oct 2002 | EP |
2 813 683 | Mar 2002 | FR |
2 312 054 | Oct 1997 | GB |
WO 9113304 | Sep 1991 | WO |
WO 0206984 | Jan 2002 | WO |
WO 0237375 | May 2002 | WO |
WO 2007108906 | Sep 2007 | WO |
WO 2008054231 | May 2008 | WO |
WO 2013126579 | Aug 2013 | WO |
WO 2013134325 | Sep 2013 | WO |
WO 2013134544 | Sep 2013 | WO |
WO 2013142218 | Sep 2013 | WO |
WO 2013158571 | Oct 2013 | WO |
WO 2013158572 | Oct 2013 | WO |
WO 2013158576 | Oct 2013 | WO |
WO 2013176800 | Nov 2013 | WO |
WO 2013180925 | Dec 2013 | WO |
WO 2014168844 | Oct 2014 | WO |
WO 2014182566 | Nov 2014 | WO |
WO 2014210531 | Dec 2014 | WO |
WO 2015006351 | Jan 2015 | WO |
WO 2015013030 | Jan 2015 | WO |
WO 2015013031 | Jan 2015 | WO |
2015069325 | May 2015 | WO |
2015069950 | May 2015 | WO |
2015073569 | May 2015 | WO |
Entry |
---|
Office Action in U.S. Appl. No. 13/485,850, dated Mar. 19, 2015. |
Office Action in U.S. Appl. No. 13/485,866, dated May 7, 2015. |
Office Action in U.S. Appl. No. 13/485,883, dated May 20, 2015. |
Office Action in U.S. Appl. No. 13/485,916, dated Mar. 27, 2015. |
Office Action in U.S. Appl. No. 13/646,632, dated Mar. 26, 2015. |
Office Action in U.S. Appl. No. 13/685,575, dated May 5, 2015. |
Office Action in U.S. Appl. No. 13/888,353, dated Mar. 26, 2015. |
Notice of Allowance in U.S. Appl. No. 13/921,078, dated Apr. 1, 2015. |
Notice of Allowance in U.S. Appl. No. 13/931,733, dated Jun. 11, 2015. |
Notice of Allowance in U.S. Appl. No. 14/044,851, dated Mar. 31, 2015. |
Office Action in U.S. Appl. No. 14/203,353, dated Mar. 31. 2015. |
Office Action in U.S. Appl. No. 14/260,115, dated Apr. 16, 2015. |
Office Action in U.S. Appl. No. 14/466,805, dated Apr. 13, 2015. |
Office Action in U.S. Appl. No. 14/286,627, dated Apr. 24, 2015. |
Office Action in U.S. Appl. No. 14/466,824, dated May 7, 2015. |
Office Actio in U.S. Appl. No. 14/467,433, dated May 8, 2015. |
Notice of Allowance in U.S. Appl. No. 14/306,111, dated Mar. 17, 2015. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/044700, dated May 18, 2015. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/065281, dated Mar. 13, 2015. |
Aernecke, M.J. et al., “Optical-fiber Arrays for Vapor Sensing”, Sensors and Actuators B: Chemical, Nov. 2009, vol. 142, Issue 2, pp. 464-469. |
Anslyn, E.V., “Supramolecular Analytical Chemistry”, The Journal of Organic Chemistry, Feb. 2, 2007, vol. 72, No. 3, pp. 687-699. |
Arora, P. et al., “An overview of transducers as platform for the rapid detection of foodborne pathogens”, Appl. Microbial. Biotechnol., vol. 97, Issue 5, pp. 1829-1840, Jan. 18, 2013 (Published online). |
“Automated Fruit Recognition” Fraunhofer, accessed online Nov. 13, 2014 and, available at http://www.iosb.fraunhofer.de/servlet/is/33328/. |
Bell, S. et al., “Report on nutrient losses and gains factors used in European food composition databases”, Technical Report, Apr. 2006, 66 pages (Retrieved from the Internet on Mar. 2, 2015 at: http://www.eurofir.net). |
Chaudhry, Q. et al., “Applications and Implications of Nanotechnologies for the Food Sector”, Food Additives and Contaminants: Part A, Mar. 2008, vol. 25, Issue 3, pp. 241-258. |
Cheftel, J. Claude, “Food and Nutrition Labelling in the European Union”, Food Chemistry 93.3, Dec. 2005, pp. 531-550, retrieved on Mar. 10, 2013 from URL: <http://www.sciencedirect.com/science/article/pii/S0308814604008581>. |
Chung, I-C. et al., “A Portable Electrochemical Sensor for Caffeine and (−) Epigallocatechin Gallate Based on Molecularly Imprinted Poly(ethylene-co-vinyl alcohol) Recognition Element”, J Nanosci Nanotechnol., vol. 11, No. 12, Dec. 2011, pp. 10633-10638. |
“Cool runnings needed for fine wines,” AFP, Apr. 28, 2008, retrieved from internet URL http://www.google.com/hostednews/afp/article/ALeqM5hm5gRK3maWqEJppJOBObR71THV on Feb. 10, 2014. |
Composition of Foods Raw, Processed, Prepared USDA National Nutrient Database for Standard Reference, Release 26 Documentation and User Guide, U.S. Department of Agriculture Agricultural Research Service, Aug. 2013 (revised Nov. 2013), 136 pages, accessed on its website, at http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Data/SR26/sr26_doc.pdf. |
De Vos, K. et al., “Multiplexed antibody detection with an array of silicon-on-insulator microring resonators”, IEEE, Photonics Journal, vol. 1, Issue 4, Oct. 2009, pp. 225-235. |
Diller, K.R., “Stress Protein Expression Kinetics”, Annual Review of Biomedical Engineering, 2006, vol. 8, pp. 403-424. |
Dorokhin, D. et al., “Imaging surface plasmon resonance for multiplex microassay sensing of mycotoxins”, Analytical and Bioanalytical Chemistry, vol. 400, Issue 9, published online Apr. 12, 2011, pp. 3005-3011. |
Ebarvia, et al, “Biomimetic piezoelectric quartz sensor for caffeine based on a molecularly imprinted polymer”, Analytical and Bioanalytical Chemistry, vol. 378, Issue 5, Mar. 2004, published online Jan. 27, 2004, pp. 1331-1337. |
Etherington, Darrell, “iCarte Turns the iPhone Into an RFID Reader,” Gigaom, Nov. 18, 2009 (downloaded Oct. 3, 2013, from URL http://gigaom.com/2009/11/18/icarte-turns-the-iphone-into-an-rfid-reader/). |
Focke, M. et al., “Lab-on-a-Foil: microfluidics on thin and flexible films”, Lab on a Chip, vol. 10, Issue 11, published online Mar. 19, 2010, pp. 1365-1386. |
Frankel, E.N., “Chemistry of Extra Virgin Olive Oil: Adulteration, Oxidative Stability, and Antioxidants”, Journal of Agricultural and Food Chemistry, 2010, vol. 58 (10), pp. 5991-6006. |
Garcia-Gonzalez, D.L. et al., “Research in Olive Oil: Challenges for the Near Future”, Journal of Agricultural and Food Chemistry, 2010, vol. 58, Issue 24, pp. 12569-12577. |
Gartia, M. et al., “Colorimetric plasmon resonance imaging using nano lycurgus cup arrays”, Advanced Optical Materials, vol. 1, Issue 1, Jan. 2013, pp. 68-76. |
Ghasemi-Varnamkhasti, M. et al., “Biomimetric-based odor and taste sensing systems to food quality and safety characterization: An overview on basic principles and recent achievements”, Journal of Food Engineering, vol. 100, Issue 3, Oct. 2010, pp. 377-387. |
Grate, J.W., “Acoustic Wave Microsensor Arrays for Vapor Sensing”, Chemical Reviews, 2000, vol. 100, No. 7, pp. 2627-2647. |
Greenfield, H. et al., “Food composition data,” FAO, 2003 (“FAO”). |
Hayano-Kanashiro, C. et al., “Analysis of Gene Expression and Physiological Responses in Three Mexican Maize Landraces Under Drought Stress and Recovery Irrigation”, PLoS One, Oct. 2009, vol. 4, Issue 10, e7531, pp. 1-19. |
Hierlemann, A. et al., “Higher-Order Chemical Sensing”, Chemical Reviews, 2008, vol. 108, No. 2, pp. 563-613. |
Hoffman, B., “IBM Announces Food Traceability Technology”, Food+Tech Connect, Oct. 19, 2011, 2 pages. |
Hsieh, M-D. et al., “Limits of Recognition for Simple Vapor Mixtures Determined with a Microsensor Array”, Analytical Chemistry, Apr. 1, 2004, vol. 76, No. 7, pp. 1885-1895. |
Huang, et al., “A passive radiofrequency pH sensing tag for wireless food quality monitoring”, IEEE Sensors Journal, vol. 12, Issue 3, Mar. 2012, pp. 487-495. |
Hugh, J. “Recipe Calculations: Where Do We Stand?”, Proceedings of the 12th National Nutrient Databank Conference, Houston, Texas, Apr. 12, 1987, pp. 135-139 (Retrieved from the Internet on Feb. 13, 2015 at http://www.nutrientdataconf.org/PastConf/NDBC12/5-2_Joseph.pdf). |
James, D. et al., “Chemical Sensors for Electronic Nose Systems”, Microchimica Acta, Feb. 2005, vol. 149, pp. 1-17. |
Janata, J. et al., “Conducting Polymers in Electronic Chemical Sensors”, Nature Materials, Jan. 2003, vol. 2, pp. 19-24. |
Kaume, L. et al., “The Blackberry Fruit: A Review on Its Composition and Chemistry, Metabolism and Bioavailability, and Health Benefits”, Journal of Agricultural and Food Chemistry, 2012, vol. 60 (23), pp. 5716-5727. |
Kharif, Olga, “Janne Haverinen: Mapping the Great Indoors”, Bloomberg BusinessWeek, May 9, 2012, retrieved from URL: <http://www.businessweek.com/articles/2012-08-09/janne-haverinen-mapping-the-great-indoors on Apr. 12, 2013>. |
Kingsmore, S.F., “Multiplexed Protein Measurement: Technologies and Applications of Protein and Antibody Arrays”, Nature Reviews Drug Discovery, Apr. 2006, vol. 5, pp. 310-321. |
Kumar, A. et al., “Study of fiber optic sugar sensor”, Pramana, vol. 67, Issue 2, Aug. 2006, pp. 383-387. |
Kwon, H. et al., “Fluorescent DNAs printed on paper: Sensing food spoilage and ripening in the vapor phase”, Chemical Science, vol. 3, Issue 8, published online May 17, 2012, pp. 2542-2549. |
Lago, F.C. et al., “FINS Methodology to Identification of Sardines and Related Species in Canned Products and Detection of Mixture by Means of SNP Analysis Systems”, European Food Research and Technology, Jun. 2011, vol. 232(6), pp. 1077-1086. |
Lago, F.C. et al., “Genetic Identification of Horse Mackerel and Related Species in Seafood Products by Means of Forensically Informative Nucleotide Sequencing Methodology”, Journal of Agricultural and Food Chemistry, 2011, vol. 59 (6), pp. 2223-2228. |
Lewis, N.S., “Comparisons Between Mammalian and Artificial Olfaction Based on Arrays of Carbon Black-Polymer Composite Vapor Detectors”, Accounts of Chemical Research, 2004, vol. 37, No. 9, pp. 663-672. |
Lin, et al., “Multiplex fiber-optic biosensor using multiple particle plasmon resonances”, International Society for Optics and Photonics: Third Asia Pacific Optical Sensors Conference, vol. 8351, Sydney, Australia, Jan. 31, 2012, pp. 83512S1-83512S7. |
Martins-Lopes, P. et al., “DNA Markers for Portuguese Olive Oil Fingerprinting”, Journal of Agricultural and Food Chemistry, 2008, vol. 56 (24), pp. 11786-11791. |
Montealegre, C. et al., “Traceability Markers to the Botanical Origin in Olive Oils”, Journal of Agricultural and Food Chemistry, 2010, vol. 58, Issue 1, pp. 28-38. |
Montesinos, E., “Plant-associated Microorganisms: a View from the Scope of Microbiology”, International Microbiology, 2003, vol. 6, Issue 4, pp. 221-223. |
Ni, et al., “Gene Expression and Regulation of Higher Plants Under Soil Water Stress”, Current Genomics, Jun. 2009, vol. 10, pp. 269-280. |
Perks, B., “Fighting Food Fraud with Science”, Text Reproduced from Chemistry World, 2007, vol. 4, Issue 9, pp. 48-52. |
Preechaburana, et al., “Surface Plasmon Resonance Chemical Sensing on Cell Phones”, Angewandte Chemie International Edition, vol. 51, Issue 46, pp. 11585-11588, first published online Oct. 16, 2012. |
Primrose, S. et al., “Food Forensics: Methods for Determining the Authenticity of Foodstuffs”, Trends in Food Science & Technology, Dec. 2010, vol. 2, Issue 12, pp. 582-590. |
Rashidi, L. et al., “The Applications of Nanotechnology in Food Industry”, Critical Reviews in Food Science and Nutrition, 2011, vol. 51, Issue 8, pp. 723-730. |
Ricci, F. et al., “A review on novel developments and applications of immunosensors in food analysis”, Analytica Chimica Acta, vol. 605, Issue 2, Dec. 19, 2007, pp. 111-129. |
Roche, PJR, et al., “A Camera Phone Localised Surface Plasmon Biosensing Platform Towards Low-Cost Label-Free Diagnostic Testing”, Journal of Sensors, vol. 2011, 2011, 7 pages. |
Röck, F. et al., “Electronic Nose: Current Status and Future Trends”, Chemical Reviews, 2008, vol. 108, No. 2, pp. 705-725. |
Scampicchio, M. et al., “Optical nanoprobes based on gold nanoparticles for sugar sensing”, Nanotechnology, vol. 20, Issue 13, Apr. 1, 2009, 5 pages. |
Sinclair, D.A. et al., “Unlocking the Secrets of Longevity Genes”, Scientific AmErikan, Mar. 2006, vol. 294, Issue 3, pp. 48-57. |
“SIRA Technologies Food Sentinal System Thermal Barcode for Packaging”, Sustainable is Good: Lifestyle and Design Blog, Mar. 4, 2009, 2 pages. |
Srinivas, P.R. et al., “Nanotechnology Research: Applications in Nutritional Sciences”, The Journal of Nutrition, Symposium-Nanotechnology Research: Applications in Nutritional Sciences, Jan. 2010, vol. 140, No. 1, pp. 119-124. |
Staggers, N. et al., “Nanotechnology: The Coming Revolution and its Implications for Consumers, Clinicians, and Informatics”, Nursing Outlook, Sep.-Oct. 2008, vol. 56, No. 5, pp. 268-274. |
Suslick, B.A. et al., “Discrimination of Complex Mixtures by a Colorimetric Sensor Array: Coffee Aromas”, Analytical Chemistry, Mar. 1, 2010, vol. 82, No. 5, pp. 2067-2073. |
Thakur, M. et al., “Food Traceability, R&D in Norway”, Food Technology, Apr. 2012, p. 42-46. |
Valero, C., et al., “Design Guidelines for a Quality Assessment System of Fresh Fruits in Fruit Centers and Hypermarkets”, Abstract, Agriculture Engineering International: the CIGR Journal of Scientific Research and Development, vol. II, Aug. 2000, 20 pages. Available online at http://dspace.library.cornell.edu/retrieve/237/, accessed Feb. 19, 2015. |
Walt, D.R., “Electronic Noses: Wake Up and Smell the Coffee”, Analytical Chemistry, Feb. 1, 2005, vol. 77, Issue 3, p. A-45. |
Wolfbeis, O.S., “Materials for Fluorescence-based Optical Chemical Sensors”, Journal of Materials Chemistry, 2005, vol. 15, pp. 2657-2669. |
Zerebecki, R.A. et al., “Temperature Tolerance and Stress Proteins as Mechanisms of Invasive Species Success”, PLoS One, Apr. 2011, vol. 6, Issue 4, e14806, pp. 1-7. |
Zhu, H. et al., “Quantum dot enabled detection of Escherichia coli using a cell-phone”, ANALYST, vol. 137, Issue 11, Jun. 7, 2012, pp. 2541-2544. |
Zou, M-Q et al., “Rapid Authentication of Olive Oil Adulteration by Raman Spectrometry”, Journal of Agricultural and Food Chemistry, 2009, vol. 57, Issue 14, pp. 6001-6006. |
Office Action in U.S. Appl. No. 13/485,850, dated May 9, 2013. |
Office Action in U.S. Appl. No. 13/485,850, dated Sep. 30, 2013. |
Office Action in U.S. Appl. No. 13/485,850, dated Mar. 20, 2014. |
Office Action in U.S. Appl. No. 13/485,850, dated Sep. 29, 2014. |
Office Action in U.S. Appl. No. 13/485,863, dated Feb. 9, 2015. |
Office Action in U.S. Appl. No. 13/485,878, dated Oct. 24, 2013. |
Office Action in U.S. Appl. No. 13/485,878, dated Jun. 5, 2014. |
Advisory Action in U.S. Appl. No. 13/485,878, dated Sep. 16, 2014. |
Office Action in U.S. Appl. No. 13/485,883, dated Feb. 3, 2015. |
Office Action in U.S. Appl. No. 13/485,900, dated Feb. 3, 2015. |
Office Action in U.S. Appl. No. 13/560,965, dated Feb. 1, 2013. |
Notice of Allowance in U.S. Appl. No. 13/560,965, dated Mar. 22, 2013. |
Office Action in U.S. Appl. No. 13/602,040, dated Oct. 23, 2013. |
Office Action in U.S. Appl. No. 13/602,040, dated Jul. 17, 2014. |
Office Action in U.S. Appl. No. 13/685,575, dated May 6, 2013. |
Office Action in U.S. Appl. No. 13/685,575, dated Oct. 24, 2013. |
Office Action in U.S. Appl. No. 13/685,575, dated Oct. 27, 2014. |
Office Action in U.S. Appl. No. 13/684,113, dated Dec. 15, 2014. |
Office Action in U.S. Appl. No. 13/729,548, dated Dec. 2, 2014. |
Office Action in U.S. Appl. No. 13/732,050, dated Oct. 24, 2013. |
Office Action in U.S. Appl. No. 13/732,050, dated Apr. 10, 2014. |
Office Action in U.S. Appl. No. 13/750,804, dated Mar. 12, 2013. |
Notice of Allowance in U.S. Appl. No. 13/750,804, dated May 31, 2013. |
Office Action in U.S. Appl. No. 13/771,004, dated May 15, 2013. |
Office Action in U.S. Appl. No. 13/771,004, dated Jul. 8, 2013. |
Office Action in U.S. Appl. No. 13/771,004, dated Apr. 4, 2014. |
Office Action in U.S. Appl. No. 13/771,004, dated Mar. 10, 2015. |
Office Action in U.S. Appl. No. 13/900,426, dated Aug. 8, 2013. |
Notice of Allowance in U.S. Appl. No. 13/900,426, dated Dec. 16, 2013. |
Office Action in U.S. Appl. No. 13/861,300 dated Feb. 24, 2015. |
Office Action in U.S. Appl. No. 13/888,353, dated May 1, 2014. |
Office Action in U.S. Appl. No. 13/888,353, dated Oct. 1, 2014. |
Office Action in U.S. Appl. No. 13/921,078, dated Nov. 4, 2014. |
Office Action in U.S. Appl. No. 13/931,733, dated Nov. 6, 2014. |
Office Action in U.S. Appl. No. 13/931,733, dated Mar. 10, 2015. |
Office Action in U.S. Appl. No. 13/931,744, dated Aug. 20, 2013. |
Notice of Allowance in U.S. Appl. No. 13/931,744, dated Feb. 28, 2014. |
Office Action in U.S. Appl. No. 13/937,167, dated Oct. 28, 2013. |
Office Action in U.S. Appl. No. 13/937,167, dated Apr. 14, 2014. |
Office Action in U.S. Appl. No. 13/948,004, dated Oct. 24, 2013. |
Office Action in U.S. Appl. No. 13/948,004, dated Jun. 11, 2014. |
Office Action in U.S. Appl. No. 14/044,851, dated Jan. 5, 2015. |
Office Action in U.S. Appl. No. 14/047,817, dated Nov. 29, 2013. |
Notice of Allowance in U.S. Appl. No. 14/047,817, dated Apr. 14, 2014. |
Office Action in U.S. Appl. No. 14/059,441, dated Feb. 11, 2014. |
Office Action in U.S. Appl. No. 14/059,441, dated Jul. 10, 2014. |
Notice of Allowance in U.S. Appl. No. 14/059,441, dated Jan. 5, 2015. |
Office Action in U.S. Appl. No. 14/074,664, dated Jan. 8, 2014. |
Notice of Allowance in U.S. Appl. No. 14/074,664, dated Jun. 2, 2014. |
Office Action in U.S. Appl. No. 14/137,963, dated Aug. 5, 2014. |
Notice of Allowance in U.S. Appl. No. 14/137,963, dated Jan. 28, 2015. |
Office Action in U.S. Appl. No. 14/304,671, dated Feb. 4, 2015. |
Office Action in U.S. Appl. No. 14/306,111, dated Nov. 13, 2014. |
Office Action in U.S. Appl. No. 29/497,888, dated Nov. 19, 2014. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/027148, dated Jun. 18, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/029219, dated Jun. 20, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/029686, dated May 13, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/031106, dated May 31, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/36666, dated Oct. 4, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/036668, dated Dec. 6, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/036670, dated Aug. 19, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/036673, dated Aug. 20, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2013/040445, dated Oct. 25, 2013. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/033084, dated Mar. 6, 2015. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/036570, dated Mar. 10, 2015. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/044696, dated Oct. 10, 2014. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/045796, dated Oct. 15, 2014. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/045798, dated Oct. 15, 2014. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/045807, dated Jan. 22, 2015. |
PCT International Search Report and Written Opinion in International Application No. PCT/US14/59186, dated Dec. 22, 2014. |
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/064434, dated Feb. 20, 2015. |
Statement in accordance with the Notice from the European Patent Office, dated Oct. 1, 2007, concerning business methods. |
Notice from the European Patent Office, dated Oct. 1, 2007, concerning business methods, Official Journal EPO, pp. 592-593. |
Extended European Search Report in European Application No. 13731655.0, dated Feb. 24, 2014. |
Communication Pursuant to Article 94(3) in European Application No. 13731655.0, dated Jan. 22, 2015. |
Extended European Search Report in European Application No. 13757669.0, dated Jan. 31, 2014. |
European Examination Report in European Application No. 13757669.0, dated Oct. 13, 2014. |
Extended European Search Report in European Application No. 13751912.0, dated Feb. 25, 2015. |
Number | Date | Country | |
---|---|---|---|
20150100350 A1 | Apr 2015 | US |
Number | Date | Country | |
---|---|---|---|
61888451 | Oct 2013 | US |